Lung Cancer (EGFR Mutation): Molecular Oncology Tumor Boards

This free case-based activity includes a crowd-sourced discussion of 58 year old previously healthy male who presents with papillary thyroid cancer (PTC) with metastasis to lungs, neck/chest lymph nodes and possibly bone.

Originally posted on a forum in the ASCO Connection, participants now have the opportunity to claim a CME, completion, or participation certificate for completing this activity.


Learning Objectives

  • Analyze the molecular testing options available for Non- Small Cell Lung Cancer and apply predictive biomarker testing guidelines
  • Discuss the clinical trial data on first line treatment therapies for patients with non-small cell lung cancer harboring mutations in the epidermal growth factor receptor (EGFR)
  • Discuss the management of patients with non-small cell lung cancer who develop acquired resistance to EGFR tyrosine kinase inhibitors

Continuing Education Credit

1 Credit/Point is available for participation in this course. Certificate and credit types available include:

  • AMA PRA Category 1 Credits™ 
  • Certificate of Participation may be used to confer credit; however, all final decisions regarding the awarding of credits will be made by the licensing organization to which the credits are submitted.
  • Certificate of Completion may be used to document participation, but no credit will be conferred.
Important Notes
  • This course expires on December 16, 2018. Participants must complete all necessary course components by this date to receive credit.